STAT+: Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Eli Lilly reported that its Phase 3 trial of retatrutide produced an average 28.3% weight loss after 80 weeks among participants who remained on the highest dose.
- Retatrutide saw 11% of patients on the highest dose discontinue due to adverse events.
- Study participants (including those who stopped) achieved a 25% average weight loss across the trial.
- Wegovy had discontinuation rates up to 7% in pivotal trials.
- Zepbound had discontinuation rates up to 7% in pivotal trials.
Why it matters: Patients with obesity gain a potent new therapy, but the 11% discontinuation rate limits adoption, while insurers and clinicians must weigh efficacy against safety and cost.
